Loading
A phase 1/2 trial of Dose Level 1, VNX-101 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, follicular lymphoma and mantle cell lymphoma, run by Vironexis Biotherapeutics Inc., now recruiting.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) is a phase 1/2 interventional study registered as NCT06533579 by Vironexis Biotherapeutics Inc., with 32 participants planned, started 2025-05-30 and due to reach its primary completion in 2027-06. Interventions recorded: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 and Dose Level 4, VNX-101.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Mantle cell lymphoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/